Demethylation

Linkage of Cancer and Lupus in Gliomas Patients

Retrieved on: 
Monday, March 25, 2024
CD86, OS, TME, Gene, Transforming growth factor beta, CD68, Survival, LGG, Ligand, TGFB2, CD276, IDH, STAT1, Inflammation, Central nervous system, Patient, RNA, Tumor microenvironment, Cancer, Messenger, Macrophage, SLE, Expression, TAM, Treatment, Neoplasm, IRF5, Therapy, TGF, IRF1, TGFB, OTCQB, Demethylation, Vaccine

Dr. Vuong Trieu, CEO and Chairman of Oncotelic, stated, ”Our R&D team has discovered crosstalk between the TGF-β and IFN signaling pathways, linking gliomas and Systemic Lupus Erythematosus (SLE).

Key Points: 
  • Dr. Vuong Trieu, CEO and Chairman of Oncotelic, stated, ”Our R&D team has discovered crosstalk between the TGF-β and IFN signaling pathways, linking gliomas and Systemic Lupus Erythematosus (SLE).
  • Understanding the role of IRF5 in both SLE and cancer opens an avenue for targeting IRF5 or its downstream pathways.
  • LGG patients expressing high levels of TGFB2 and IFNGR2 are over-represented in IDH wild-type tumor samples, suggesting that TGFB2 and IFNGR2 mRNA can be therapeutically targeted in these high-risk patients.
  • Therefore, to improve OS in LGG patients, combination therapies must target TGFB2 and IFN-γ activation (via IRF5 inhibition) or immune therapies targeted against CD276/B7-H3

TellBio Announces Consecutive Manuscripts Showcasing Promising Translational and Clinical Applications of the TellDx Platform in Prostate Cancer and Tailoring Therapy in Advanced Breast Cancer

Retrieved on: 
Thursday, July 6, 2023
DNA, Data, Methylation, Doctor of Pharmacy, Breast Cancer Research and Treatment, Progression-free survival, SERD, Demethylation, ESR1, Neoplasm, Breast, Cancer, Fulvestrant, NKT, Mutation, DRS, Prostate, Biomarker, RNA, Radiation therapy, Doctor of Philosophy, Chinese, Associate, Assistant, Harvard Medical School, HR, CTC, Endocrine therapy resistance in breast cancer, Publication, Patient, MBC, Breast cancer, Prostate cancer, Triple-negative breast cancer, DOI, Biology, Hospital, Research, MPH, Massachusetts General Hospital, Metastasis, Pharmaceutical industry, Medical imaging, Vaccine, MD, Cell, Treatment, Medicine

BEVERLY, Mass., July 06, 2023 (GLOBE NEWSWIRE) -- TellBio, Inc., a development stage biotechnology company focused on revolutionizing detection of cancer through its unique and proprietary circulating tumor cell (CTC) technology, the TellDx System, announces two publications that demonstrate the utility of CTC molecular analyses in patients with prostate cancer or advanced breast cancer. The papers entitled, “DNA hypomethylation silences anti-tumor immune genes in early prostate cancer and circulating tumor cells,” and “Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells” were published in Cell (DOI: 10.1016/j.cell.2023.05.028) and Breast Cancer Research and Treatment (DOI: 10.1007/s10549-023-06998-w), respectively. 

Key Points: 
  • “These publications continue to highlight the potential utility of the TellDx technology in a spectrum of clinical settings ranging from early localized disease to advanced metastatic disease.
  • Prostate cancer generally evolves slowly from an indolent low-grade localized condition to poorly differentiated tumor with high likelihood of aggressive metastatic CTCs associated with poor prognosis.
  • Among patients with localized prostate cancer, less than 15% of the cancers are detectable with short circulating tumor DNA hypermethylation assays.
  • Age-matched healthy donors showed minimal signal whereas patients with localized prostate cancer or metastatic prostate cancer revealed a significant DNA hypomethylation signal.